The company has received approval from the DCGI for Fasenra (Benralizumab solution for injection in a single dose prefilled syringe30 mg/ml) for patients with severe asthma (eosinophilic asthma), AstraZeneca India said in a statement.
Copyright © 2024 | WordPress Theme by MH Themes
